377 related articles for article (PubMed ID: 21575460)
41. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
Urol Oncol; 2007; 25(6):468-75. PubMed ID: 18047954
[TBL] [Abstract][Full Text] [Related]
42. p130Cas, E-cadherin and β-catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance.
Hu X; Ruan Y; Cheng F; Yu W; Zhang X; Larré S
Int J Urol; 2011 Sep; 18(9):630-7. PubMed ID: 21672035
[TBL] [Abstract][Full Text] [Related]
43. Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer.
Kamai T; Takagi K; Asami H; Ito Y; Oshima H; Yoshida KI
Br J Cancer; 2001 May; 84(9):1242-51. PubMed ID: 11336477
[TBL] [Abstract][Full Text] [Related]
44. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
45. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
46. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer.
Sonpavde G; Khan MM; Lerner SP; Svatek RS; Novara G; Karakiewicz PI; Skinner E; Tilki D; Kassouf W; Fradet Y; Dinney CP; Fritsche HM; Izawa JI; Bastian PJ; Ficarra V; Schoenberg M; Sagalowsky AI; Lotan Y; Shariat SF
J Urol; 2011 Feb; 185(2):456-61. PubMed ID: 21167527
[TBL] [Abstract][Full Text] [Related]
47. [Analysis of the relationship between expression of caveolin-1 and prognosis in bladder transitional cell carcinoma].
Ruan J; Weng ZL
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):429-31. PubMed ID: 20819483
[TBL] [Abstract][Full Text] [Related]
48. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
[TBL] [Abstract][Full Text] [Related]
50. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile.
Dip N; Reis ST; Timoszczuk LS; Viana NI; Piantino CB; Morais DR; Moura CM; Abe DK; Silva IA; Srougi M; Dall'Oglio MF; Leite KR
J Urol; 2012 Nov; 188(5):1951-6. PubMed ID: 22999546
[TBL] [Abstract][Full Text] [Related]
51. CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis.
Afonso J; Longatto-Filho A; Baltazar F; Sousa N; Costa FE; Morais A; Amaro T; Lopes C; Santos LL
Eur J Surg Oncol; 2011 Sep; 37(9):811-7. PubMed ID: 21733655
[TBL] [Abstract][Full Text] [Related]
52. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder.
Miyamoto H; Yao JL; Chaux A; Zheng Y; Hsu I; Izumi K; Chang C; Messing EM; Netto GJ; Yeh S
BJU Int; 2012 Jun; 109(11):1716-26. PubMed ID: 22221549
[TBL] [Abstract][Full Text] [Related]
53. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
Guo CC; Fine SW; Epstein JI
Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
[TBL] [Abstract][Full Text] [Related]
54. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer.
Theodorescu D; Sapinoso LM; Conaway MR; Oxford G; Hampton GM; Frierson HF
Clin Cancer Res; 2004 Jun; 10(11):3800-6. PubMed ID: 15173088
[TBL] [Abstract][Full Text] [Related]
55. Significance of collagenase 3 (matrix metalloproteinase 13) in invasive bladder cancer: correlation with pathological parameters.
Rodríguez Faba O; Fernández Gómez JM; Palou Redorta J; Escaf Barmadah S; Vizoso F; Villavicencio Mavrich H
Urol Int; 2007; 78(2):140-4. PubMed ID: 17293654
[TBL] [Abstract][Full Text] [Related]
56. The prognostic significance of nuclear CSE1L in urinary bladder urothelial carcinomas.
Chang CC; Tai CJ; Su TC; Shen KH; Lin SH; Yeh CM; Yeh KT; Lin YM; Jiang MC
Ann Diagn Pathol; 2012 Oct; 16(5):362-8. PubMed ID: 22476051
[TBL] [Abstract][Full Text] [Related]
57. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
58. Plasmacytoid urothelial carcinoma of the bladder: histological and clinical features of 5 cases.
Fritsche HM; Burger M; Denzinger S; Legal W; Goebell PJ; Hartmann A
J Urol; 2008 Nov; 180(5):1923-7. PubMed ID: 18801525
[TBL] [Abstract][Full Text] [Related]
59. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection.
Behnsawy HM; Miyake H; Abdalla MA; Sayed MA; Ahmed Ael-F; Fujisawa M
Urol Oncol; 2011; 29(5):495-501. PubMed ID: 19914103
[TBL] [Abstract][Full Text] [Related]
60. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]